[go: up one dir, main page]

AR105413A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Info

Publication number
AR105413A1
AR105413A1 ARP160100272A ARP160100272A AR105413A1 AR 105413 A1 AR105413 A1 AR 105413A1 AR P160100272 A ARP160100272 A AR P160100272A AR P160100272 A ARP160100272 A AR P160100272A AR 105413 A1 AR105413 A1 AR 105413A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
sucralfate
particle size
Prior art date
Application number
ARP160100272A
Other languages
Spanish (es)
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of AR105413A1 publication Critical patent/AR105413A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para el tratamiento de enfermedades gastrointestinales caracterizado porque comprende ranitidina, sucralfato y subcitrato de bismuto como componentes activos y que satisface por lo menos una de las siguientes condiciones: (a) el sucralfato tiene un tamaño de partícula promedio de 1 a 25 mm, (b) el subcitrato de bismuto tiene un tamaño de partícula promedio de 5 a 90 mm.Claim 1: A pharmaceutical composition for the treatment of gastrointestinal diseases characterized in that it comprises ranitidine, sucralfate and bismuth subcitrate as active components and which satisfies at least one of the following conditions: (a) sucralfate has an average particle size of 1 at 25 mm, (b) the bismuth subcitrate has an average particle size of 5 to 90 mm.

ARP160100272A 2015-01-30 2016-01-29 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AR105413A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30

Publications (1)

Publication Number Publication Date
AR105413A1 true AR105413A1 (en) 2017-10-04

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100272A AR105413A1 (en) 2015-01-30 2016-01-29 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX375765B (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
WO2019199134A1 (en) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (en) * 1987-03-09 1993-03-04 Procter & Gamble COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
DE69525620T2 (en) * 1994-04-26 2002-10-17 Chugai Seiyaku K.K., Tokio/Tokyo METHOD FOR PRODUCING MEL-GRANULATED SUCRAL FATE PREPARATION
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
JP5516401B2 (en) * 2008-07-01 2014-06-11 ライオン株式会社 Solid oral preparation
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
WO2016122226A3 (en) 2016-09-15
MX2017007567A (en) 2017-10-19
EA032385B1 (en) 2019-05-31
SA517382016B1 (en) 2021-03-18
JP2018503672A (en) 2018-02-08
JP6419347B2 (en) 2018-11-07
CL2017001680A1 (en) 2018-01-12
MX375765B (en) 2025-03-07
CN107205947B (en) 2020-05-22
TW201639559A (en) 2016-11-16
ECSP17038599A (en) 2017-09-29
KR101583452B1 (en) 2016-01-11
PH12017550051A1 (en) 2018-01-29
UA116517C2 (en) 2018-03-26
PE20171340A1 (en) 2017-09-13
TWI635859B (en) 2018-09-21
MY195824A (en) 2023-02-22
EP3250199A2 (en) 2017-12-06
GEP20196941B (en) 2019-01-10
KR101583452B9 (en) 2022-05-02
CN107205947A (en) 2017-09-26
EP3250199A4 (en) 2018-08-08
KR20160094268A (en) 2016-08-09
EA032385B9 (en) 2019-07-31
BR112017013857A2 (en) 2018-02-27
CO2017006222A2 (en) 2017-09-20
WO2016122226A2 (en) 2016-08-04
EA201791458A1 (en) 2017-11-30
MA41432A (en) 2017-12-05

Similar Documents

Publication Publication Date Title
MX2022015755A (en) Pth prodrugs.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
MX378273B (en) ACTIVE COMPOUNDS TOWARDS BROMODOMAINS.
CL2016002971A1 (en) Combination.
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
CL2018000565A1 (en) Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others.
EA201790787A1 (en) REDUCTION OF VISCOSITY OF PHARMACEUTICAL COMPOSITIONS
CL2015002546A1 (en) Substituted 3-phenylpropylamine derivatives for the treatment of diseases and ophthalmic disorders
BR112018005754A2 (en) isoxazoline-substituted benzamides and analogues such as insecticides.
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.
ECSP17044282A (en) Insulin glargine / lixisenatide fixed ratio formulation
CO2017002472A2 (en) Abiraterone acetate formulation
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
WO2014153009A3 (en) Thiosaccharide mucolytic agents
CL2016002879A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2018002164A (en) ANTI-EPHA4 ANTIBODY.
MX2017000676A (en) ORITAVANCINA HIGH PURITY AND METHOD TO PRODUCE THE SAME.
MX2017007000A (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same.
WO2017079403A3 (en) Polymeric nanoparticles
BR112015016033A2 (en) compositions and methods for treating bacterial infections
EA201791845A1 (en) SOLID FORMS OF MENAHINOLS
HUE057871T2 (en) Hyaluronan conjugates, methods and compositions containing medicinal active ingredients
DOP2016000251A (en) WNT SIGNALING ROAD INHIBITORS

Legal Events

Date Code Title Description
FC Refusal